Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's mission is to develop precision neuromedicines that address significant unmet needs in CNS, aiming to overcome the limitations of conventional treatments by targeting specific neuronal receptor complexes. Headquartered in Boston, Massachusetts, Rapport Therapeutics leverages its proprietary Receptor Associated Protein (RAP) technology platform to achieve this goal.

The company's core technology is built upon pioneering discoveries related to Receptor Associated Proteins (RAPs), which play crucial roles in regulating receptor expression and function. This enables the development of CNS drugs with enhanced specificity for receptor variants and brain regions, potentially leading to improved efficacy and tolerability. Rapport's lead investigational drug, RAP-219, is a clinical-stage small molecule designed to selectively inhibit TARPγ8-containing AMPARs. It is currently being evaluated as a potential treatment for focal onset seizures (FOS), bipolar mania, and diabetic peripheral neuropathic pain. Additionally, Rapport is advancing nicotinic acetylcholine receptor (nAChR) programs for chronic pain and migraine, as well as hearing and vestibular disorders.

Rapport Therapeutics became a publicly traded company in June 2024, listing on NASDAQ under the ticker symbol "RAPP." Abraham N. Ceesay serves as the Chief Executive Officer, leading the company's strategic direction. Recent notable developments include positive topline results from the Phase 2a clinical trial of RAP-219 in focal onset seizures, reported in September 2025, which demonstrated significant seizure reduction and a favorable tolerability profile. The company plans to initiate a Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio into primary generalized tonic-clonic seizures (PGTCS) with a planned Phase 3 start in the first half of 2027. Rapport also announced a strategic collaboration with Tenacia Biotechnology in March 2026 for the development and commercialization of RAP-219 in Greater China.